Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate

Although the overwhelming majority of community-acquired pneumonia (CAP) in children is caused by viral infections, treatment of CAP is among the most common indications for antibiotic use in children. This is largely driven by the imprecision of clinical diagnostic tools to differentiate viral from...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiotos, Kathleen, Gerber, Jeffrey S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531865/
https://www.ncbi.nlm.nih.gov/pubmed/34704033
http://dx.doi.org/10.1093/jacamr/dlab153
_version_ 1784586954760781824
author Chiotos, Kathleen
Gerber, Jeffrey S
author_facet Chiotos, Kathleen
Gerber, Jeffrey S
author_sort Chiotos, Kathleen
collection PubMed
description Although the overwhelming majority of community-acquired pneumonia (CAP) in children is caused by viral infections, treatment of CAP is among the most common indications for antibiotic use in children. This is largely driven by the imprecision of clinical diagnostic tools to differentiate viral from bacterial pneumonia and highlights the need for improved approaches to optimizing management of CAP in children. In this issue of JAC-Antimicrobial Resistance, we present a PRO/CON debate that discusses the clinical utility of procalcitonin in children with CAP.
format Online
Article
Text
id pubmed-8531865
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-85318652021-10-25 Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate Chiotos, Kathleen Gerber, Jeffrey S JAC Antimicrob Resist Viewpoint Although the overwhelming majority of community-acquired pneumonia (CAP) in children is caused by viral infections, treatment of CAP is among the most common indications for antibiotic use in children. This is largely driven by the imprecision of clinical diagnostic tools to differentiate viral from bacterial pneumonia and highlights the need for improved approaches to optimizing management of CAP in children. In this issue of JAC-Antimicrobial Resistance, we present a PRO/CON debate that discusses the clinical utility of procalcitonin in children with CAP. Oxford University Press 2021-10-22 /pmc/articles/PMC8531865/ /pubmed/34704033 http://dx.doi.org/10.1093/jacamr/dlab153 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Viewpoint
Chiotos, Kathleen
Gerber, Jeffrey S
Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate
title Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate
title_full Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate
title_fullStr Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate
title_full_unstemmed Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate
title_short Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate
title_sort does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? a pro/con debate
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531865/
https://www.ncbi.nlm.nih.gov/pubmed/34704033
http://dx.doi.org/10.1093/jacamr/dlab153
work_keys_str_mv AT chiotoskathleen doesprocalcitoninhaveclinicalutilityinthemanagementofpaediatriccommunityacquiredpneumoniaaprocondebate
AT gerberjeffreys doesprocalcitoninhaveclinicalutilityinthemanagementofpaediatriccommunityacquiredpneumoniaaprocondebate

Ejemplares similares